menu toggle

340B

Manufacturer updates

340B Advisory Services


April 17th, 2023

AbbVie

Effective April 17th, 2023, AbbVie will only provide 340B priced product to a single Contract Pharmacy located within 40 miles of the parent site if a hospital covered entity doesn’t have an in-house pharmacy. Federal Grantees not subject to limitations. *Updated policy now includes 90 drugs from original 25 added to exclusion list

Contact: 

February 1st, 2022

AbbVie

Effective February 1st, 2022, AbbVie will only provide 340B priced product to a single Contract Pharmacy if Covered Entity does not have an in-house pharmacy location. Grantees not subject to limitations.


*Imbruvica effective April 1st, 2022 

Contact: 

April 11th, 2023

Amgen

Effective April 11th, 2023, Amgen will only provide 340B priced product to a single Contract Pharmacy located within 40 miles of the parent site if the non-grantee doesn’t have an in-house pharmacy. Federal Grantees not subject to limitations.

January 3rd, 2022

Amgen

Effective January 3rd, 2022, Amgen will only provide 340B priced product to a single Contract Pharmacy if the Covered Entity does not have an in-house pharmacy location. Policy is limited to four drugs and doesn’t include Federal Grantees.

Contact: 

support@340Besp.com

January 1st, 2021

Amgen 

Effective January 1st, 2021, Amgen will no longer provide voluntary, “340B like” discounts, on orphan designated drugs to participating Covered Entities.

Contact:
340Brelations@amgen.com

October 12th, 2023

Astellas

Effective October 17th, 2023, Astellas will provide 340B pricing for Xtandi® to an unlimited number of contract pharmacies located in Arkansas for covered entities in the state of Arkansas and an unlimited number of contract pharmacies located in Louisiana for covered entities in the state of Louisiana.

Contact:
support@340besp.com

July 3rd, 2023

Astellas

Effective September 1st, 2023, Astellas will only provide 340B pricing for Xtandi® to a single contract pharmacy if a hospital covered entity doesn’t have an in-house pharmacy. Federal Grantees not subject to limitations.  

Contact: 
support@340BESP.com

July 3rd, 2023

AstraZeneca

Effective August 1st, 2023, AstraZeneca will transition the administration of their 340B contract pharmacy program to a third-party vendor.

Contact: 
support@340BESP.com 

 

June 1st, 2022

AstraZeneca

Effective June 1st, 2022, AstraZeneca will no longer provide voluntary, “340B like” discounts, on orphan designated drugs to participating Covered Entities.


*Calquence & Lynparza (October 1st, 2022) and Fasenra (January 1st, 2023) voluntary contracts restored.

October 1st, 2020

AstraZeneca

Effective October 1st, 2020, AstraZeneca will only provide 340B priced product to a single Contract Pharmacy.



Contact: membership@AstraZeneca.com 

June 12th, 2023

Bausch Health

Effective June 26th, 2023, Bausch Health will only provide 340B priced products to a single contract pharmacy located within 40 miles of the parent site if the entity does not have an in-house pharmacy. 

Contact: 

July 1st, 2022

Bausch Health

Effective August 1st, 2022, Bausch Health will only provide 340B priced product to a single Contract Pharmacy if Covered Entity doesn’t have an in-house pharmacy. Multiple contract pharmacy access is permissible through provision of claims data via 340B ESP. 

Contact:
support@340Besp.com


April 28th, 2023

Bayer

Effective June 1st, 2023, Bayer will only provide 340B priced product to a single Contract Pharmacy located within 40 miles of the parent site if a hospital covered entity doesn’t have an in-house pharmacy. Federal Grantees not subject to limitations.

*Updated policy now includes Adempas

February 1st, 2023

Bayer

Effective March 1, 2023, Bayer will only provide 340B priced product to a single Contract Pharmacy location if the hospital Covered Entity does not have an in-house pharmacy. Multiple contract pharmacy access is permissible through provision of claims data via 340B ESP. Grantees not subject to limitations.

December 1st, 2023

Biogen

Effective December 1st, 2023, Biogen will add Zurzuvae™ to its policy. A 340B hospital covered entity may designate a single contract pharmacy within the limited distribution pharmacy network if the entity does not have an in-house pharmacy capable of dispensing Zurzuvae™. The policy remains the same for Avonex® and Plegridy®.
Federal Grantees not subject to limitations.

Contact: 
support@340besp.com

December 12th, 2022

Biogen

Effective February 1st, 2023, Biogen will only provide 340B priced product to a single Contract Pharmacy location if the Covered Entity does not have an in-house pharmacy. Policy is limited to two drugs and doesn’t include Federal Grantees.

June 22nd, 2023

Boehringer Ingelheim

Effective August 1st, 2023, Boehringer Ingelheim will only provide 340B priced products to a single contract pharmacy located within 40 miles of the parent site if the entity does not have an in-house pharmacy. No central fill pharmacies.

Any covered entity that does not have an in-house pharmacy capable of dispensing specialty products may designate 1 specialty pharmacy from within BI’s limited distribution network for the purpose of dispensing OFEV.

Contact: 

September 1st, 2022

Boehringer Ingelheim

Boehringer Ingelheim announced effective September 1st, 2022, an expansion to their contract pharmacy policy to include grantees enrolled in the Consolidated Health Center Program (CH/CHC). All other Federal Grantees not subject to limitations.

Contact:
support@340besp.com

December 1st, 2021

Boehringer Ingelheim

Effective December 1st, 2021, BI will add its specialty product, OFEV, to the list of products subject to its 340B Contract Pharmacy policy. BI restrictions from August 1st, 2021, remain effective. Link to both notices below. 

Contact:
support@340Besp.com

October 6th, 2023

Bristol Myers Squibb

Effective November 1st, 2023, BMS will recognize up to three designated 340B contract pharmacy locations per 340B hospital that lacks an entity-owned pharmacy: one for IMiDs, a second for non-IMiDs, and a third for Camzyos.

Contact: 
support@340besp.com 

January 14th, 2022

Bristol Myers Squibb

Effective March 1st, 2022, BMS will recognize up to two designated 340B contract pharmacy
locations per 340B hospital that lacks an entity-owned pharmacy: one for IMiDs and a second for non-IMiDs. Federal Grantees not subject to limitations on non-IMiD products.


*Camzyos effective July 1st, 2022 

Contact:

Clovis

At this time, Clovis won’t be implementing its partnership with Kalderos to effectuate 340B drug discounted prices for 340B Contract Pharmacies. Clovis’ products remain available through all historically available channels.

Contact:
priceadmin@clovisoncology.com

October 2nd, 2023

Eisai

Effective November 1, 2023, Eisai will only provide 340B priced products to a single contract pharmacy if the entity does not have an in-house pharmacy. 

Federal Grantees not subject to limitations.

*Additional contract pharmacy options may be available to Arkansas and Louisiana hospital covered entities

Contact: 
support@340besp.com  

November 6th, 2023

Eli Lilly

Effective November 16th, 2023, Eli Lilly will only provide 340B priced products to a single contract pharmacy if the entity does not have an in-house or wholly-owned pharmacy.  Eli Lilly’s insulin policy remains the same.

Contact: 
340B@lilly.com

December 10th, 2021

Eli Lilly

Lilly announced on December 10th, 2021, an expansion to their contract pharmacy policy allowing 340B priced product to a Contract Pharmacy if Covered Entity provides Claims Level Detail via 340B ESP platform for dispenses on or after October 29th, 2021.

Contact:
340B@lilly.com

September 1st, 2020

Eli Lilly

Effective September 1st, 2020, Lilly restricted access for 340B priced product to Contract Pharmacies, except insulin.


Contact:
340B@lilly.com

September 1st, 2023

EMD Serono

Effective October 1st, 2023, EMD Serono’s updated contract pharmacy policy will include all EMD Serono marketed Products. EMD Serono will only provide 340B pricing products to a single contract pharmacy if a hospital covered entity doesn’t have an in-house pharmacy. 

*Serostim®: covered entities may designate one additional contract pharmacy location in EMDS’s secure distribution network (the “SND”) for the purpose of dispensing Serostim only.   

Federal Grantees not subject to limitations.

Contact: 
support@340besp.com  

February 1st, 2023

EMD Serono

Effective March 1, 2023, EMD Serono (EMDS) will only provide 340B pricing for REBIF and GONAL-F to a single Contract Pharmacy if a hospital Covered Entity does not have an in-house pharmacy location. Grantees not subject to limitations.

June 7th, 2022

Exelixis

Effective July 6th, 2022, Exelixis will only provide 340B pricing on COMETRIQ and CABOMETYX to a single Contract Pharmacy within the specialty pharmacy network if the Covered Entity does not have an in-house pharmacy location. Federal Grantees not subject to limitations. 

Contact:
340B@exelixis.com

January 1st, 2024

Gilead

Effective January 30th, 2024, Gilead will require covered entities to submit claims level data via 340BESP for their branded HCV products purchased at the 340B price for wholly-owned pharmacies.

Contact: 
support@340besp.com

March 16th, 2022

Gilead

Effective May 2nd, 2022, Gilead will only provide a 340B price on branded hepatitis C products to a single Contract Pharmacy if the Covered Entity does not have an in-house pharmacy location. 

 

Contact: 

October 31st, 2023

GlaxoSmith
Kline

Effective November 1st, 2023, GSK will allow Arkansas-based and Louisiana-based covered entities to place “Bill to/Ship to” replenishment orders to their HRSA designated contract pharmacies located within the respective states. For specialty/oncology products part of the limited pharmacy network, the contract pharmacies must be a part of GSK’s limited pharmacy network. 

GSK will honor Arkansas- and Louisiana-based covered entities’ replenishment orders associated with a covered product dispensed within the respective states on or after August 1st, 2023.

Contact: 
support@340besp.com

September 25th, 2023

GlaxoSmith
Kline

GSK added OJJAARA (Momelotinib) Tablets to its 340B Contract Pharmacy Policy 

Contact: 
support@340besp.com 
 

May 1st, 2023

GlaxoSmith
Kline

Effective May 1, 2023, GSK will only provide 340B priced product to a single Contract Pharmacy if a covered entity doesn’t have an in-house pharmacy. An additional specialty pharmacy part of a limited pharmacy network may be designated.

*Updated policy now includes all GSK drugs

Contact:

support@340BESP.com

July 1st, 2022

GlaxoSmith Kline

Effective July 1st, 2022, GSK will no longer offer voluntary 340B pricing on two orphan drugs (NUCALA and ZEJULA) to Covered Entities subject to the 340B orphan drug exclusion. This change will not impact Covered Entities not subject to the orphan drug exclusion.

Contact:
US.340B@gsk.com 

April 1st, 2022

GlaxoSmith Kline

Effective April 1st, 2022, GSK will only provide 340B priced product to a single Contract Pharmacy if the Covered Entity does not have an in-house pharmacy location. Federal Grantees not subject to limitations.

Contact

 

September 18th, 2023

Incyte

Effective October 16th, 2023, Incyte will only provide 340B pricing on Opzelura® to a single contract pharmacy located within 40 miles of the parent site if a hospital entity does not have an in-house pharmacy.

Federal Grantees are not subject to limitations.

Contact: 

September 11th, 2023

Jazz

Effective October 9th, 2023, Jazz will only provide 340B pricing for Epidiolex® to a single contract pharmacy if a hospital covered entity doesn’t have an in-house pharmacy. 

Federal Grantees not subject to limitations.

Contact: 
support@340besp.com 

March 7th, 2023

Janssen

Effective March 7th, 2023, Janssen will only provide 340B priced product to a single Contract Pharmacy located within 40 miles of the parent site if the non-grantee doesn’t have an in-house pharmacy. An additional specialty pharmacy part of limited distribution system may be designated. Federal Grantees not subject to limitations.

Contact: 

January 1st, 2022

Janssen

Effective January 1st, 2022, Janssen will no longer offer voluntary 340B pricing on orphan drugs to Covered Entities subject to the 340B orphan drug exclusion. This change will not impact separate agreements with impacted Covered Entities.

July 31st, 2023

Merck

Effective July 31st, 2023, Merck will provide 340B priced products to an unlimited number of contract pharmacies in the state of Louisiana and Arkansas if the hospital or CH covered entity registers and submits 340B claims data. Federal Grantees (except CH grantee entities) not subject to limitations.  

Contact: 
340bdata@merck.com

May 10th, 2023

Merck

Effective June 12, 2023, Merck will only provide 340B priced product to a single contract pharmacy location, within 40 miles of the hospital Covered Entity or Consolidated Health Center, if they don’t have an in-house pharmacy. All other Federal Grantees are not subject to limitations. 

Contact: 

May 31st, 2022

Merck

Merck announced on April 28th, 2022, an expansion to their 340B Program integrity initiative to include Consolidated Health Centers. All previous requirements remain effective.

Contact:

September 1st, 2021

Merck

Effective September 1st, 2021, Merck will only provide 340B priced product to a single Contract Pharmacy if the Covered Entity does not have an in-house pharmacy location. Grantees not subject to limitations. 

Contact:
340Bdata@merck.com

May 1st, 2023

Novartis

Effective May 1st, 2023, Novartis will only provide 340B priced product to a single Contract Pharmacy if the hospital covered entity doesn’t have an in-house pharmacy. Federal Grantees not subject to limitations.

Contact:

Novartis.340B@novartis.com

November 16th, 2020

Novartis

Effective November 16th, 2020, Novartis will restrict 340B priced product to Contract Pharmacies based on a 40 mile radius for hospital Covered Entities. Federal Grantees not subject to limitations.

Contact: Novartis.340B@novartis.com

January 19th, 2024

Novo Nordisk

Effective February 1st, 2024, Novo Nordisk updated its contract pharmacy policy for Arkansas hospital covered entities only. They will allow two contract pharmacy designations for all Arkansas hospital covered entities without the provision of claims data. With the provision of claims data, an unlimited number of contract pharmacies are allowed if they are located within the state of Arkansas.
Federal Grantees not subject to limitations

Contact: 
support@340Besp.com
340BInfo@novonordisk.com  

June 1st, 2023

Novo Nordisk

Effective July 1st, 2023, Novo Nordisk will allow up to two contract pharmacy locations per 340B hospital (one retail, one specialty). Federal Grantees are not subject to limitations.

Contact: 

 

December 2nd, 2022

Novo Nordisk

Novo Nordisk announced on December 2nd, 2022, an expansion to their contract pharmacy policy allowing 340B priced product to a Contract Pharmacy if Covered Entity provides Claims Level Detail via 340B ESP platform for dispenses on or after January 1st, 2023.

Contact:

340BInfo@novonordisk.com

January 24th, 2022

Novo Nordisk

Novo Nordisk announced effective February 1st, 2022, an expansion to their hospital contract pharmacy policy. 340B hospitals that lack a wholly owned pharmacy can designate two contract pharmacy locations: one retail and one specialty.


Contact:
 

January, 1st 2021

Novo Nordisk

Effective January 1st, 2021, Novo Nordisk will restrict 340B priced product to Contract Pharmacies for hospital Covered Entities. Federal Grantees not subject to limitations.


Contact: 340BInfo@novonordisk.com 

November 1st, 2023

Organon

Effective December 1st, 2023, Organon will allow Arkansas-based and Louisiana-based covered entities to place “Bill to/Ship to” replenishment orders to unlimited contract pharmacies if claims level data is submitted via 340B ESP.

Contact: 

June 1st, 2023

Organon

Effective July 1st, 2023, Organon will only provide 340B priced product to a single contract pharmacy location if the hospital Covered Entity provides Claims Level Detail via 340B ESP platform. Federal Grantees not subject to limitations.

Contact: 

 

October 2nd, 2023

Pfizer

Effective November 1st, 2023, Pfizer will include additional products to the defined distribution model currently in place for Xeljanz. They will only provide the 340B price to a single Contract Pharmacy if the hospital covered entity doesn’t have an in-house pharmacy. 
Federal Grantees not subject to limitations.
*No modifications to Pfizer’s DON policy

Contact: 
340BCP@pfizer.com

August 11th, 2023

Pfizer

Effective November 1st, 2023, Pfizer will change its process on acquiring Vyndamax® and Vyndaquel® at the 340B ceiling prices. A 340B covered entity may either apply to have its specialty pharmacy be a VYNDA Network Institution or establish a contract pharmacy relationship with a specialty contract pharmacy in the VYNDA Network.

Federal Grantees not subject to limitations.

Contact: 
340BCP@pfizer.com

May 1st, 2023

Pfizer

Effective May 1st, 2023, Pfizer will only provide Xeljanz at a 340B price to a single Contract Pharmacy if the hospital covered entity doesn’t have an in-house pharmacy. Federal Grantees not subject to limitations.

*No modifications to Pfizer’s DON policy

Contact:

340BCP@pfizer.com

March 1st, 2022

Pfizer

Effective March 1st, 2022, Pfizer will recognize up to two designated contract pharmacy locations per 340B hospital that lacks a wholly owned: one for Xeljanz and a second for oral oncology products. Multiple contract pharmacy access is permissible through provision of claims data via 340B ESP.  
 
Contact:

November 1st, 2023

Sandoz

Effective December 1st, 2023, Sandoz will only provide 340B priced products to a single Contract Pharmacy located within 40 miles of the parent site, regardless of if a hospital covered entity has an in-house or wholly owned pharmacy, through provision of claims data via 340B ESP. Federal Grantees and covered entity hospitals located in Arkansas and Louisiana are not subject to limitations.

Contact:
support@340BESP.com 

May 15th, 2023

Sanofi

Effective June 1, 2023, Sanofi will only provide 340B priced product to a single contract pharmacy location if the hospital Covered Entity doesn’t have an in-house pharmacy. Federal Grantees, Children’s Hospitals, and Free Standing Cancer Hospitals are not subject to limitations. 

Contact: 

February 1st, 2021

Sanofi

Effective March 1st, 2021, Sanofi will only provide 340B priced product to a Contract Pharmacy if Covered Entity provides Claims Level Detail via 340B ESP platform. 


Contact: Sanofi340Boperations@sanofi.com
 

January 16th, 2024

Takeda

Effective February 16th, 2024, Takeda will include Inclusig, Alunbrig and Fruzaqla in its 340B Contract Pharmacy Policy. Only pharmacies in Takeda’s limited distribution network may be designated so the 40-mileage restriction does not apply.
Federal Grantees not subject to limitations

Contact: 
support@340besp.com

December 15th, 2023

Takeda

Effective January 22nd, 2024, Takeda will only provide 340B pricing for select products to a single independent contract pharmacy or wholly owned contract pharmacy(ies) within 40 miles* of the parent site through provision of claims data via 340B ESP if a hospital covered entity doesn’t have an in-house pharmacy. If a hospital covered entity  does have an in-house pharmacy, it may also designate its wholly owned contract pharmacy(ies) through provision of claims data via 340B ESP.
Federal Grantees not subject to limitations
*Exception: Entyvio

Contact: support@340besp.com 

October 23rd, 2023

Teva

Effective November 6th, 2023, Teva will include Austedo and Austedo XR product families to its contract pharmacy policy.

Contact:
support@340besp.com 

 

September 20th, 2023

Teva

Effective September 26th, 2023, Teva will provide 340B priced products to an unlimited number of contract pharmacies for covered entities in the state of Arkansas.

Contact: 

July 31st, 2023

Teva

Effective August 1st, 2023, Teva will provide 340B priced products to an unlimited number of contract pharmacies in the state of Louisiana. Federal Grantees not subject to limitations. 

Contact: 
support@340Besp.com

June 8th, 2023

Teva

Effective July 5th, 2023, Teva will only provide 340B priced products to a single contract pharmacy located within 40 miles of the parent site if the non-grantee entity does not have an in-house pharmacy. Federal Grantees not subject to limitations.

Contact: 
support@340Besp.com

 

October 19th, 2023

UCB

Bimzelx was added to UCB’s contract pharmacy policy on October 19th, 2023.

Contact: 
340B@ucb.com

 

September 5th, 2023

UCB

Effective October 2nd, 2023, UCB updated its contract pharmacy policy to exclude wholly owned (and common ownership) pharmacy exemption. UCB will only provide 340B pricing to a single contract pharmacy located within 40 miles of the parent site if a hospital covered entity doesn’t have an in-house pharmacy.

Federal Grantees not subject to limitations.

Contact: 

November 22nd, 2021

UCB

Effective December 13th, 2021, UCB will only provide 340B priced product to a single Contract Pharmacy if the Covered Entity does not have an in-house pharmacy location. Federal Grantees not subject to limitations.

Contact:
340B@ucb.com

July 23rd, 2021

United Therapeutics

Effective December 1st, 2021, United Therapeutics will only provide 340B priced product to a Contract Pharmacy if Covered Entity provides Claims Level Detail via 340B ESP platform. 

Contact:
340B@unither.com

Woodward

Effective April 1, 2023, select Woodward Pharma products will only be available at a 340B ceiling price through direct distribution via DCS and no longer available via full line distributor 340B accounts.

*12 additional NDCs effective March 15th, 2023

Contact: 
340b-clientsservices@
directcustomersolutions.com